Mark Hancock

Mark Hancock sells 63,680 shares for $2,248,415.32 under pre-arranged 10b5-1 plan at PACS

Mark Hancock, Co-Founder and Executive Vice Chair, executed 2 separate sales totaling 63,680 shares for $2,248,415.32 on 2026-06-17 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-11. This is a scheduled transaction rather than a discretionary decision. The sale reduced his holdings from 54,366,277 shares to 54,302,597 shares, a net change of -0.1% versus pre-transaction holdings. His prior trades at PACS showed mixed outcomes: a 2024-09-09 sale with 30-day return of +7.6% and 90-day return of -57.2%, and a 2024-04-15 sale with 30-day return of +35.0% and 90-day return of +47.7%, indicating no consistent pattern at this ticker. With current stock price at $37.77 against a 52-week high of $43.08, the stock is -12.3% from its peak and +12.0% over the last 90 days.

Co-Founder Hancock sells 236,320 shares for $8,551,140.55 via scheduled 10b5-1 plan

Mark Hancock, Co-Founder and Executive Vice Chair of PACS Group, executed 4 separate sales totaling 236,320 shares for $8,551,140.55 at a blended average price of $36.18 per share on June 15–16, 2026. This sale represents a -0.4% reduction of his 54.60M share pre-transaction holdings, leaving him with 54,366,277 shares post-transaction. Critically, the FLAG notation confirms this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-11, meaning the sales were scheduled, not discretionary. At his current holdings of 54.37M shares, Hancock retains substantial economic exposure to PACS; the modest scale of this divestiture (0.4% of position) and its scheduled nature limit the signal content for investor inference about conviction or outlook.

Co-Founder Hancock Mark sold 8,128,352 shares of PACS at $36.25 on 2024-09-09, reducing stake by -15.3%; stock up 29.8% over 90 days post-sale.

Hancock Mark, Co-Founder & Executive Vice Chair, executed a large open-market sale of 8,128,352 shares (valued at $294,652,760.00) on 2024-09-09, reducing his holdings from 53,254,551 shares to 45,126,199 shares. The sale occurred at $36.25 per share, compared to a current price of $38.34; notably, PACS stock has appreciated 29.8% over the 90 days following the transaction, indicating this sale was not well-timed against subsequent price action. His cross-ticker track record shows zero well-timed sells across all holdings (0.00% well-timed rate), and his prior PACS sale on 2024-04-15 also failed to precede a decline, returning +47.7% over the ensuing 90 days. Despite the significant disposition of a founder's stake at a substantial dollar value, the persistent pattern of the insider selling into strength rather than before downturns, combined with net income of $-10,910,000.00 against revenue of $981,846,000.00, warrants attention to the gap between insider selling activity and realized market weakness.